ACE and cancer: Another intriguing finding in our study was that cancer risk was significantly associated with angiotensin-converting enzyme inhibitors (ACEIs) (AOR 0.854, 95% CI 0.829-0.880; P<.001) but not with angiotensin II antagonists (ARBs), even though both ACEIs and ARBs pharmacologically share a similar pathway.